Assembly Biosciences, Inc operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome. It is involved in the development of core inhibitors that inhibit the functional activities of HBV core protein at various points in the viral lifecycle.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Phone833-509-4583
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$14.80 million
Profitability
Miscellaneous
Employees95
Next Earnings Date11/14/2019 (Estimated)
OptionableOptionable
Assembly Biosciences (NASDAQ:ASMB) Frequently Asked Questions
What is Assembly Biosciences' stock symbol?
Assembly Biosciences trades on the NASDAQ under the ticker symbol "ASMB."
How were Assembly Biosciences' earnings last quarter?
Assembly Biosciences Inc (NASDAQ:ASMB) issued its quarterly earnings results on Monday, August, 5th. The biopharmaceutical company reported ($0.72) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($1.13) by $0.41. The biopharmaceutical company had revenue of $3.08 million for the quarter, compared to analysts' expectations of $3.90 million. Assembly Biosciences had a negative net margin of 622.25% and a negative return on equity of 46.33%. View Assembly Biosciences' Earnings History.
When is Assembly Biosciences' next earnings date?
What price target have analysts set for ASMB?
4 equities research analysts have issued 1 year target prices for Assembly Biosciences' shares. Their forecasts range from $30.00 to $45.00. On average, they anticipate Assembly Biosciences' stock price to reach $39.00 in the next year. This suggests a possible upside of 212.2% from the stock's current price. View Analyst Price Targets for Assembly Biosciences.
What is the consensus analysts' recommendation for Assembly Biosciences?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Assembly Biosciences in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Assembly Biosciences.
What are Wall Street analysts saying about Assembly Biosciences stock?
Here are some recent quotes from research analysts about Assembly Biosciences stock:
- 1. According to Zacks Investment Research, "Assembly Biosciences, Inc. is a biopharmaceutical company. It develops therapies for infectious diseases and other disorders of the gastrointestinal (GI) system. Assembly's product portfolio consists of two late stage assets: VEN 307 for relief from pain associated with anal fissures and VEN 308 for the treatment of fecal incontinence. The Company is also developing novel microbiome-based technology for targeted oral delivery of therapeutic bacteria, complex proteins, viral antigens and small molecules to treat intractable infectious diseases of the GI tract, such as C. difficile infections. Assembly Biosciences Inc., formerly known as Ventrus Biosciences, Inc., is based in New York. " (8/13/2019)
- 2. Chardan Capital analysts commented, "We are also encouraged by the initiation of the phase Ib clinical trial (NCT03923478) for ABI-M201, Assembly’s rationally-designed consortium live biotherapeutic product for UC. We broadly favor this approach to microbiome medicines (MMs) development. Assembly reported $173.8 mm in cash and cash equivalents, providing a runway into 2021." (8/7/2019)
Has Assembly Biosciences been receiving favorable news coverage?
Media stories about ASMB stock have been trending negative on Saturday, according to InfoTrie. The research group rates the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Assembly Biosciences earned a media sentiment score of -2.3 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Assembly Biosciences.
Who are some of Assembly Biosciences' key competitors?
Some companies that are related to Assembly Biosciences include Phibro Animal Health (PAHC), Opko Health (OPK), Theravance Biopharma (TBPH), Athenex (ATNX), Gossamer Bio (GOSS), Epizyme (EPZM), Innoviva (INVA), Odonate Therapeutics (ODT), ArQule (ARQL), Radius Health (RDUS), Esperion Therapeutics (ESPR), Amphastar Pharmaceuticals (AMPH), Dicerna Pharmaceuticals (DRNA), Stoke Therapeutics (STOK) and Zymeworks (ZYME).
What other stocks do shareholders of Assembly Biosciences own?
Who are Assembly Biosciences' key executives?
Assembly Biosciences' management team includes the folowing people:
- Mr. Derek A. Small, Co-Founder, Pres, CEO & Director (Age 43)
- Dr. Uri A. Lopatin, Co-Founder, Chief Medical Officer and VP of R&D (Age 47)
- Dr. Richard J. Colonno, Exec. VP & Chief Scientific Officer of Virology Operations (Age 69)
- Mr. Thomas E. Rollins, Exec. Officer (Age 63)
- Mr. David J. Barrett CPA, Consultant (Age 43)
Who are Assembly Biosciences' major shareholders?
Assembly Biosciences' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Jennison Associates LLC (10.00%), Jennison Associates LLC (9.94%), BlackRock Inc. (6.90%), Vanguard Group Inc. (4.77%), Janus Henderson Group PLC (3.74%) and Janus Henderson Group PLC (3.74%). Company insiders that own Assembly Biosciences stock include Derek A Small, Uri A Lopatin and William R Ringo. View Institutional Ownership Trends for Assembly Biosciences.
Which institutional investors are selling Assembly Biosciences stock?
ASMB stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace LLP, Capital Impact Advisors LLC, Zacks Investment Management, Northern Trust Corp, Prudential Financial Inc., Private Advisors LLC, Emerald Advisers LLC and Wells Fargo & Company MN. View Insider Buying and Selling for Assembly Biosciences.
Which institutional investors are buying Assembly Biosciences stock?
ASMB stock was purchased by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Citadel Advisors LLC, Vanguard Group Inc., Rock Springs Capital Management LP, Renaissance Technologies LLC, Morgan Stanley, Jennison Associates LLC and Jennison Associates LLC. View Insider Buying and Selling for Assembly Biosciences.
How do I buy shares of Assembly Biosciences?
Shares of ASMB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Assembly Biosciences' stock price today?
One share of ASMB stock can currently be purchased for approximately $12.49.
How big of a company is Assembly Biosciences?
Assembly Biosciences has a market capitalization of $321.12 million and generates $14.80 million in revenue each year. The biopharmaceutical company earns $-90,750,000.00 in net income (profit) each year or ($3.98) on an earnings per share basis. Assembly Biosciences employs 95 workers across the globe.View Additional Information About Assembly Biosciences.
What is Assembly Biosciences' official website?
How can I contact Assembly Biosciences?
Assembly Biosciences' mailing address is 11711 NORTH MERIDIAN STREET SUITE 310, CARMEL IN, 46032. The biopharmaceutical company can be reached via phone at 833-509-4583 or via email at [email protected]
MarketBeat Community Rating for Assembly Biosciences (NASDAQ ASMB)
MarketBeat's community ratings are surveys of what our community members think about Assembly Biosciences and other stocks. Vote "Outperform" if you believe ASMB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ASMB will underperform the S&P 500 over the long term. You may vote once every thirty days.
